XBiotech wins 2nd fast-track status for therapeutic antibody

01/8/2013 | American City Business Journals

The FDA granted a second fast-track designation to XBiotech USA's therapeutic monoclonal antibody MABp1 as a treatment for restenosis and vascular disease. The drug previously received a fast-track status for advanced cancer with related cachexia. XBiotech is seeking multiple approvals to create a new treatment paradigm -- that inhibiting chronic inflammation can address multiple diseases.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD